WellDoc BlueStar

by WellDoc  · Based in United States → — AI-powered healthtech leader connecting people to better, more personalized cardiometabolic care.
Cardiology Endocrinology Internal Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

WellDoc BlueStar is an FDA-cleared digital health solution designed to revolutionize chronic disease management. It leverages advanced artificial intelligence (AI) to provide personalized, real-time, and actionable insights to individuals living with chronic conditions, while also enhancing connections to their healthcare teams. The platform offers multi-condition support across pre-diabetes, type 1 and type 2 diabetes, hypertension, heart failure, weight management, and behavioral health, including integrated mental wellbeing and sleep support.

BlueStar functions as a Software as a Medical Device (SaMD), providing digital coaching, educational content, and motivational support. It integrates with various connected devices such as blood glucose monitors (BGM), continuous glucose monitors (CGM), blood pressure cuffs, weight scales, activity trackers, and insulin pens. The platform includes both patient-facing mobile applications (iOS, Android) and a web-based management portal for healthcare providers, facilitating data exchange and informed clinical decision-making.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven personalized coaching
  • Multi-condition support (diabetes, hypertension, heart failure, weight management, behavioral health)
  • Integration with connected devices (BGM, CGM, BP cuffs, weight scales, activity trackers, insulin pens)
  • Insulin dose recommendations (bolus, basal, premixed)
  • Real-time feedback and educational content
  • Care team portal for providers (Management Portal)
  • SMARTVisit reports for healthcare providers
  • Data logging capabilities (glucose, BP, weight, sleep, meals, exercise)
  • Secure communication system (Message Center)
  • Medication adherence support

Use Cases

  • Self-management of chronic conditions (diabetes, hypertension, heart failure)
  • Enhancing connections between patients and healthcare teams
  • Supporting insulin management (titration, bolus calculation)
  • Improving clinical outcomes (A1c reduction, blood pressure reduction, weight loss)
  • Reducing healthcare costs for health plans, systems, and employers
  • Remote patient monitoring and management

What Physicians Need to Know

Heart Failure Risk Prediction
WellDoc BlueStar provides multi-condition support for heart failure and utilizes predictive AI to identify at-risk individuals, enabling actionable interventions.
Cardiac Monitoring Integration
The platform integrates with cardiac monitors and emerging biosensor technologies, alongside other connected devices like blood pressure cuffs and weight scales, to translate real-time data into personalized guidance.
AHA/ACC Guideline Alignment
WellDoc's AI-driven coaching messages are developed based on clinical guidelines, emphasizing clinical rigor and evidence-based approaches in its chronic care management.
Real-Time Alert Capability
The system delivers real-time, personalized AI coaching messages and feedback to users. It also has the capability to alert care teams when intervention is needed based on individual health trends.
Physician Tip

WellDoc BlueStar offers a comprehensive platform for managing cardiometabolic conditions, including heart failure and hypertension, by providing continuous health data exchange and AI-driven insights through a care team portal and EHR integration. This can streamline clinical interventions, support shared decision-making, and potentially reduce the time spent per patient annually. Physicians can leverage the personalized coaching and real-time alerts to proactively manage patient care and reinforce healthy behaviors between visits. The platform's focus on clinical rigor and evidence-based approaches ensures reliable support for patient management.

WellDoc BlueStar is designed for extensive interoperability, connecting with over 400 devices and data sources. This includes continuous glucose monitors (CGMs), blood glucose meters (BGMs), blood pressure cuffs, weight scales, activity trackers, pharmacies, and lab results. The platform also offers seamless integration with Electronic Health Record (EHR) systems, such as Epic, to facilitate comprehensive data flow and enhance care coordination.

Details

Category Cardiology AI, Endocrinology & Metabolic AI, Patient Engagement & Education
Pricing Enterprise pricing; paid by health plans, health systems, or employers. — Enterprise pricing; contact WellDoc for details.
DeploymentMobile app (iOS, Android) and web-based platform
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

WellDoc BlueStar is an FDA-cleared digital health solution with multiple 510(k) clearances for adults with type 1 and type 2 diabetes. Clearances include features for bolus insulin dose recommendations, CGM integration, and basal/bolus insulin titration.
Integrations
EHR Not specified
Specialties Cardiology, Endocrinology, Internal Medicine

What the Web Says

WellDoc BlueStar is a digital health solution primarily for individuals with diabetes (Type 1 and Type 2), and also supports pre-diabetes, hypertension, and heart failure. It's an FDA-cleared software as a medical device that provides personalized, real-time AI-driven coaching, educational tools, and allows users to track various health metrics and connect with their care teams. The platform aims to empower patients in self-managing their conditions and improve communication with healthcare providers.

Overall: Mixed

Strengths

  • Syncs with multiple devices and EMR services, making data management easy for patients and providers.
  • Provides personalized, real-time AI-driven coaching messages and educational content.
  • Supports various self-management behaviors for diabetes, including medication, sleep, exercise, and diet.
  • Clinically validated with numerous peer-reviewed publications and FDA clearances.
  • Can lead to significant reductions in HbA1c and improvements in time in glucose range.
  • Enhances patient engagement, especially when recommended by a medical provider and integrated with EHR systems.

Limitations

  • User interface (UI) could be improved and some users find it outdated and hard to grasp.
  • Some users have reported bugs, such as purging meal data and incorrectly marking medications as taken.
  • Issues with direct syncing to Fitbit, requiring a workaround that strips most data.
  • The setup process can be complex due to the extensive features.
  • Lack of a dedicated mobile app for some functionalities (though the core BlueStar is an app).

Based on reviews from: G2, PMC, Well Doc - YouTube, accessdata.fda.gov, Diabetes Apps & Digital Therapeutics l BlueStar, Welldoc, AJMC, Reddit, Digital Therapeutics Alliance, Capterra

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate WellDoc BlueStar

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Welldoc
Welldoc Receives 11th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStaru00ae
Welldoc announced its 11th FDA 510(k) clearance for BlueStaru00ae, enabling the platform to provide bolus insulin dose recommendations based on continuous glucose monitoring (CGM) data. This makes Welldoc the first company to receive clearance for a CGM-informed bolus calculator for adults using multiple daily insulin injections.
2023-08
Welldoc
Welldoc Receives 10th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStaru00ae
Welldoc received its 10th FDA 510(k) clearance for BlueStaru00ae, allowing the digital health solution to use connected insulin dosing data for personalized bolus insulin dosing recommendations, with commercial availability expected in 2024.
2023-08
JMIR Diabetes
Impact of a Combined Continuous Glucose Monitoringu2013Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes
This real-world study evaluated the BlueStar digital health solution combined with the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system for adults with type 2 diabetes, showing improvements in glycemic control and engagement over three months.
2023-09
Welldoc
Welldoc Presents Data Showing Use of Digital Health Tool with AI-coaching Leads to Weight Loss and Improved Health Measures, Adding to Over 75 Publications to Date
Welldoc announced data demonstrating that its digital health application with AI-driven coaching led to significant weight loss and favorable trends in post-meal blood glucose and systolic blood pressure for individuals with type 2 diabetes.
2023-11
Welldoc
Welldoc Announces CE Mark Certification
Welldoc's BlueStaru00ae mobile app received CE mark certification as a Class IIa medical device under the European Union Medical Device Regulation (EU-MDR), allowing for expansion of its digital health solutions in the EU.
2024-03
Welldoc
Welldoc Cements AI Leadership with Dedicated AI Lab and 100+ Clinical Publications
Welldoc announced the establishment of its AI Lab, emphasizing its commitment to AI-powered, personalized cardiometabolic care, backed by 11 FDA clearances, 60 patents, and over 100 peer-reviewed publications.
2025-11
Welldoc
Welldoc's BlueStar Named 2022 u201cBest Overall Connected Healthcare Solutionu201d in 2022 MedTech Breakthrough Awards Program
Welldoc's BlueStaru00ae was recognized as the u201cBest Overall Connected Healthcare Solutionu201d in the 2022 MedTech Breakthrough Awards, highlighting its comprehensive chronic care platform for multiple conditions.
2022-05
PR Newswire
Welldoc and Lilly collaborate to integrate BlueStaru00ae app capabilities into Lilly's connected insulin solutions
Welldoc and Eli Lilly and Company announced a collaboration to integrate Welldoc's BlueStaru00ae app capabilities into Lilly's connected insulin solutions, aiming to simplify insulin use for people with diabetes.
2021-02

Videos

Product demos, reviews, and walkthroughs for WellDoc BlueStar.

View all on YouTube

Frequently Asked Questions

WellDoc BlueStar leverages AI to provide personalized, real-time coaching messages and actionable insights to individuals managing chronic conditions like diabetes. The AI analyzes patient health data, including glucose readings from connected devices, to support self-management behaviors and identify patterns that can be escalated to the healthcare provider.
WellDoc BlueStar is an FDA-cleared Software as a Medical Device (SaMD), holding multiple 510(k) clearances for diabetes management, including advanced insulin dosing recommendations. The platform adheres to rigorous quality management systems and complies with global and national health privacy mandates, such as HIPAA, ensuring secure and trustworthy data handling.
The WellDoc platform includes a Management Portal that can integrate with existing EHR systems, facilitating continuous health data exchange to healthcare providers. This integration allows care teams to efficiently view patient data and insights, supporting improved coordination and better patient outcomes without disrupting established workflows.
While BlueStar offers significant support, it is crucial to understand that it is not intended to replace direct medical care from a licensed healthcare professional, including prescriptions, diagnosis, or treatment. Its effectiveness is also dependent on consistent patient engagement and adherence to the program's guidance.
Access to WellDoc BlueStar is generally covered by health plans, health systems, or employers, rather than requiring direct payment from the patient. The solution aims to reduce overall medical expenditures and has demonstrated cost savings, potentially enabling the use of remote patient monitoring reimbursement codes for providers.
WellDoc BlueStar is supported by extensive clinical evidence, including over 100 peer-reviewed publications and multiple randomized controlled trials. Studies have consistently demonstrated significant reductions in A1C levels, improvements in glycemic control, and overall cost savings for patients with diabetes.
Yes, the digital therapeutics market for diabetes and cardiometabolic conditions is evolving, with several companies offering comparable solutions. While specific direct competitors were not detailed in the search, other platforms like Dario and Dawn Health are also recognized in the broader digital health space for chronic disease management.

Compare WellDoc BlueStar

VS
WellDoc BlueStar vs Cardiomo
Cardiology AI Adjacent · 65/100
WellDoc BlueStar is an FDA-cleared digital health solution focused on comprehensive chronic disease management for conditions like diabetes, hypertension, and heart failure, offering personalized coaching and insights through…
VS
WellDoc BlueStar vs KardiaPro
Cardiology AI Adjacent · 65/100
WellDoc BlueStar and KardiaPro are adjacent tools in the healthcare AI space, both offering FDA-cleared solutions for chronic condition management with a focus on cardiology. WellDoc BlueStar provides…
VS
WellDoc BlueStar vs ClearRead CT
Cardiology AI Adjacent · 65/100
WellDoc BlueStar is designed for patient-facing chronic disease management, offering personalized coaching and data tracking for conditions like diabetes and heart failure. In contrast, ClearRead CT is a…
VS
Ligence Heart vs WellDoc BlueStar
Cardiology AI Adjacent · 65/100
Ligence Heart is designed to enhance diagnostic efficiency and accuracy for cardiologists and sonographers by automating the analysis and reporting of echocardiography. In contrast, WellDoc BlueStar is a…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed WellDoc BlueStar

Funded through the company that built this tool.

TCP Venture Capital
VC T3
Baltimore, United States
$250k-$1M
TCP Venture Capital is an early-stage technology-focused firm based in Baltimore that invests in software and healthcare technology applications. The healthcare focus…
Health IT / Healthcare Software
TSVC
VC T3
Los Altos, United States
$250k-$1M
TSVC, based in Silicon Valley with a presence at tsvcap.com and an active Crunchbase profile, is an early-stage venture firm best known…
AI/ML in Healthcare Biotech
Icon Ventures
VC T3
Palo Alto, United States
unknown
Icon Ventures is a Palo Alto-based generalist venture firm with roughly two decades of history investing in enterprise software, infrastructure, and selectively…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
Excel Venture Management
VC T3
Boston, United States
$1M-$5M
Excel Venture Management is a Boston-based early-stage venture firm focused on life sciences and healthcare technology, with a particular thesis around what…
AI/ML in Healthcare Biotech
AI Tool Finder
AI-powered search. Results may not be comprehensive.